• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
On January 14th, Goldman Sachs issued a research report giving China Biopharmaceutical (01177.HK) a "Buy" rating with a target price of HK$6.19. This target price is based on a 12-month sum-of-the-parts valuation method, where the innovative drug pipeline is valued at RMB 69.3 billion using a discounted cash flow method, while the generic drug business is valued at RMB 46.8 billion based on a P/E ratio of 12 and a five-year CAGR of 5%. China Biopharmaceutical announced the acquisition of 100% equity in Hergia for a total price of RMB 1.2 billion, with approximately RMB 1.1 billion paid in cash and the remaining RMB 97 million to be paid in installments through new shares. Hergia is a clinical-stage biotechnology company focusing on siRNA technology, currently possessing four clinical-stage projects targeting Lp(a), ApoC3, THRbeta, and HBV, and more than 10 preclinical candidate products. This is the third acquisition by China Biopharmaceutical in two years. Goldman Sachs believes that as siRNA technology gradually becomes an important innovative model for the treatment of chronic diseases, this acquisition will strengthen China Biopharmaceuticals R&D pipeline in the fields of cardiovascular, metabolic and liver diseases, and create synergies with its existing products.According to the General Administration of Customs, China imported 9,951.6 tons of rare earths in December, compared with 5,221 tons in November.According to the General Administration of Customs, China imported 101,062 tons of rare earths from January to December.According to the General Administration of Customs, China imported 13.448 million tons of natural gas in December, compared with 11.947 million tons in November.According to the General Administration of Customs, China imported 127.865 million tons of natural gas from January to December.

Gold Price Prediction: The XAU/USD pair will fall below $1870 as yields rise ahead of Fed Chair Powell's speech

Alina Haynes

Jan 10, 2023 14:55

截屏2023-01-09 下午5.31.06_1024x576.png

 

In the Tokyo session, the gold price (XAU/USD) has fallen below the immediate resistance of $1,870.00. The precious metal has broken through the consolidation formed in the band of $1,870.00-1,881.50 as demand for US government bonds deteriorates ahead of the speech by Federal Reserve (Fed) chairman Jerome Powell on Tuesday.

 

The 10-year US Treasury yields have risen beyond 3.54 percent, dampening risk appetite. Meanwhile, S&P500 futures have become volatile following a sell-off late in Monday's session, signaling caution in establishing positions in risky assets. The US Dollar Index (DXY) is anticipated to attempt a break above the immediate resistance of 103.00 into the auction area.

 

Investors anticipate Fed Powell's speech for fresh cues, as it will provide a head start for the entirety of CY2023. Despite a sharp reduction in December wage inflation, some Fed policymakers continue to endorse a terminal rate prediction of 5.00-5.25%.

 

Mary Daly, president of the San Francisco Fed Bank, argued that interest rates between 5% and 5.25 percent are fair. Also, the president of the Atlanta Federal Reserve bank, Raphael Bostic, anticipates an interest rate peak in the range of 5% to 5.25 percent and the continuation of higher interest rates through CY2023.